Francis Spinale to Tissue Inhibitor of Metalloproteinases
This is a "connection" page, showing publications Francis Spinale has written about Tissue Inhibitor of Metalloproteinases.
Connection Strength
5.383
-
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
Score: 0.451
-
Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
Score: 0.445
-
Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
Score: 0.442
-
Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
Score: 0.390
-
Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation. 2011 Sep 13; 124(11 Suppl):S35-45.
Score: 0.372
-
Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar; 13(3):271-7.
Score: 0.352
-
Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy. Cardiol Young. 2011 Feb; 21(1):52-61.
Score: 0.350
-
Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol. 2006 Feb; 47(2):228-35.
Score: 0.252
-
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
Score: 0.236
-
Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
Score: 0.233
-
Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003 Mar; 125(3):602-10.
Score: 0.206
-
Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002 Dec 18; 40(12):2165-73.
Score: 0.203
-
Tissue inhibitor of metalloproteinase-4 deletion in mice impacts maternal cardiac function during pregnancy and postpartum. Am J Physiol Heart Circ Physiol. 2023 01 01; 324(1):H85-H99.
Score: 0.202
-
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
Score: 0.202
-
Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
Score: 0.105
-
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012 Feb; 93(2):457-63.
Score: 0.095
-
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg. 2012 Jan; 143(1):215-23.
Score: 0.094
-
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail. 2008 Feb; 10(2):125-8.
Score: 0.072
-
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
Score: 0.070
-
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 Apr; 133(4):1028-36.
Score: 0.068
-
Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation. J Thorac Cardiovasc Surg. 2006 Oct; 132(4):788-95.
Score: 0.066
-
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006 Jul 04; 114(1 Suppl):I365-70.
Score: 0.065
-
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
Score: 0.063
-
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation. 2005 Aug 30; 112(9):1274-83.
Score: 0.061
-
Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation. 2005 Mar 08; 111(9):1166-74.
Score: 0.059
-
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003 Jun 10; 107(22):2857-63.
Score: 0.052
-
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
Score: 0.051
-
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1288-95.
Score: 0.048
-
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
Score: 0.048
-
Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006 Sep; 318(3):966-73.
Score: 0.016
-
Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004 Jan 20; 109(2):262-8.
Score: 0.014